Etrumadenant

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

and more 4 locations

A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

Phase 2

Recruiting

Conditions: Urothelial Carcinoma
Metastatic Cancer

Interventions: Drug: Pemetrexed
Drug: Zimberelimab
Drug: Etrumadenant

First Posted Date: 2022-04-20

Last Posted Date: 2024-06-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT05335941

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Etrumadenant

First Posted Date: 2022-03-14

Last Posted Date: 2024-05-24

Lead Sponsor: Arcus Biosciences, Inc.

Target Recruit Count: 24

Registration Number: NCT05277012

Locations: 🇺🇸
Investigational Site, Lincoln, Nebraska, United States

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer
Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: SRF617
Drug: etrumadenant
Drug: zimberelimab

First Posted Date: 2022-01-05

Last Posted Date: 2024-05-17

Lead Sponsor: Coherus Biosciences, Inc.

Target Recruit Count: 16

Registration Number: NCT05177770

Locations: 🇺🇸
START South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇺🇸
START Mountain Region, Utah Cancer Specialists, West Valley City, Utah, United States
🇨🇦
BC Cancer - The Vancouver Centre, Vancouver, British Columbia, Canada

and more 6 locations

A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Etrumadenant
Drug: Itraconazole

First Posted Date: 2021-12-10

Last Posted Date: 2024-05-24

Lead Sponsor: Arcus Biosciences, Inc.

Target Recruit Count: 20

Registration Number: NCT05154136

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers

Phase 1

Withdrawn

Conditions: Oral Cavity Squamous Cell Carcinoma
Squamous Cell Carcinoma of Head and Neck
Hypopharynx Squamous Cell Carcinoma
Oral Cavity Cancer
Oropharynx Cancer
Pharynx Cancer
Head and Neck Cancer
Oropharynx Squamous Cell Carcinoma
Larynx Cancer
Hypopharynx Cancer

Interventions: Drug: Zimberelimab
Radiation: Radiation
Drug: Cisplatin
Drug: Etrumadenant

First Posted Date: 2021-05-19

Last Posted Date: 2023-11-30

Lead Sponsor: Jennifer Choe

Registration Number: NCT04892875

Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Non Small Cell Lung Cancer
Non-small Cell Lung Cancer
Non-small Cell Carcinoma

Interventions: Drug: Zimberelimab
Drug: Domvanalimab
Drug: Etrumadenant

First Posted Date: 2021-03-10

Last Posted Date: 2024-04-09

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 30

Registration Number: NCT04791839

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

Phase 1

Active, not recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Regorafenib
Drug: AB680
Drug: Etrumadenant
Drug: Zimberelimab
Drug: Bevacizumab
Drug: m-FOLFOX-6 regimen

First Posted Date: 2020-12-09

Last Posted Date: 2024-12-20

Lead Sponsor: Arcus Biosciences, Inc.

Target Recruit Count: 227

Registration Number: NCT04660812

Locations: 🇮🇹
Azienda Ospedaliero Universitaria Careggi-S.O.D. Patologia Medica, Firenze, Italy
🇮🇹
Azienda Ospedaliera Niguarda Ca' Granda, Milano, Italy
🇮🇹
Instituto Europeo di Oncologia, Milano, Italy

and more 46 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy